{"id":"minoxidil-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertrichosis (excessive hair growth)"},{"rate":null,"effect":"Dermatitis/contact dermatitis"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Headache (systemic formulation)"},{"rate":null,"effect":"Tachycardia (systemic formulation)"},{"rate":null,"effect":"Fluid retention (systemic formulation)"}]},"_chembl":{"chemblId":"CHEMBL802","moleculeType":"Small molecule","molecularWeight":"209.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, causing vasodilation and increased blood flow to hair follicles. It also directly stimulates hair follicle growth and extends the anagen phase of the hair growth cycle. The exact mechanism of action on hair follicles remains incompletely understood but involves both vascular and direct follicular effects.","oneSentence":"Minoxidil is a potassium channel opener that vasodilates blood vessels and may stimulate hair follicle growth through increased blood flow and prolongation of the anagen (growth) phase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:30.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male and female pattern hair loss)"},{"name":"Alopecia areata"}]},"trialDetails":[{"nctId":"NCT07273799","phase":"PHASE3","title":"Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2025-12-20","conditions":"Androgenic Alopecia","enrollment":200},{"nctId":"NCT04594018","phase":"PHASE3","title":"Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia","status":"RECRUITING","sponsor":"EMS","startDate":"2023-02-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT06924632","phase":"PHASE3","title":"Efficacy & Safety of Minoxidil SL Tablets in Men With AGA","status":"RECRUITING","sponsor":"Samson Clinical Operations Pty Ltd","startDate":"2025-07-14","conditions":"Androgenetic Alopecia, Male Pattern Baldness","enrollment":132},{"nctId":"NCT03831334","phase":"EARLY_PHASE1","title":"Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2019-04-09","conditions":"Permanent Chemotherapy-induced Alopecia","enrollment":14},{"nctId":"NCT06679556","phase":"PHASE1","title":"Phase 1 Pharmacokinetic Study of Minoxidil SL Tablets","status":"COMPLETED","sponsor":"Samson Clinical Operations Pty Ltd","startDate":"2024-11-06","conditions":"Pharmacokinetic","enrollment":12},{"nctId":"NCT06501924","phase":"PHASE3","title":"Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","status":"NOT_YET_RECRUITING","sponsor":"Applied Biology, Inc.","startDate":"2025-01-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness","enrollment":516},{"nctId":"NCT05888922","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-09","conditions":"Androgenetic Alopecia, Female Pattern Baldness","enrollment":520},{"nctId":"NCT06015516","phase":"PHASE1","title":"Bioavailability Clinical Trial of Oral Minoxidil 1 mg","status":"COMPLETED","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-02-09","conditions":"Healthy","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Minoxidil Tablets","genericName":"Minoxidil Tablets","companyName":"Industrial Farmacéutica Cantabria, S.A.","companyId":"industrial-farmac-utica-cantabria-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil is a potassium channel opener that vasodilates blood vessels and may stimulate hair follicle growth through increased blood flow and prolongation of the anagen (growth) phase. Used for Androgenetic alopecia (male and female pattern hair loss), Alopecia areata.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}